Immunome (IMNM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Meeting called to order at 9:00 A.M. Pacific Time with board, executive team, and auditors present.
Voting instructions and procedures for stockholders were reviewed.
Inspector of Elections appointed and record date for voting established as April 16, 2026.
Four proposals were presented for consideration during the meeting.
Board and executive committee updates
Election of three nominees as Class III directors to serve until the 2029 annual meeting was proposed.
Shareholder proposals
Ratification of Ernst & Young LLP as independent auditors for fiscal year ending December 31, 2026.
Advisory vote on executive compensation and on the frequency of such votes were included.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Immunome
- Varegacestat shows strong efficacy as launch nears; ADC pipeline and cash runway support growth.IMNM
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Varegacestat met all Phase 3 endpoints in desmoid tumors, with NDA filed and strong pipeline progress.IMNM
Investor presentation31 May 2026 - NDA filed for varegacestat after strong Phase 3; Q1 net loss $53.8M, cash $582.7M.IMNM
Q1 202612 May 2026 - Shareholders to vote on director elections, auditor ratification, and executive pay at the annual meeting.IMNM
Proxy filing24 Apr 2026 - 2025 achievements drove pipeline and share growth; Board recommends all proposals at 2026 meeting.IMNM
Proxy filing24 Apr 2026 - Lead asset Varegacestat nears FDA submission after strong phase III data; ADC pipeline advances.IMNM
Leerink Global Healthcare Conference 202610 Mar 2026 - Positive Phase 3 results and strong financing position support multiple 2026 milestones.IMNM
Q4 20253 Mar 2026 - Varegacestat advances toward NDA as a robust ADC pipeline and radiotherapy program gain momentum.IMNM
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Positive Phase 3 data for varegacestat and a deep ADC pipeline drive oncology innovation.IMNM
Corporate presentation3 Mar 2026